Longitudinal observation of subretinal fibrosis in Vogt-Koyanagi-Harada disease

BMC Ophthalmology

Table 1 Baseline demographics, clinical characteristics and treatments of the VKH patients with subretinal fibrosis

Pt No.	G	Age	DFV(d)	Inappropriate initial CS treatment>2w^a	IBCV (OD)	IBCV (OS)	IMTs and initial daily doses	RAU	ME	MA	Cataract/ IOL	MI	SRFRS	FBCV (OD)	FBCV (OS)	DFU (m)
1	M	23	5	–	20/80	20/100	CsA (200 mg/d) + AZA (100 mg/d)	+	+	–	+	OS	–	20/25	20/80	40
2	M	28	22	Insufficient dosing	20/2000	20/2000	CsA (200 mg/d)	+	+	–	+	OD	–	20/1000	20/16	24
3	M	52	27	Over-rapid tapering	20/100	20/330	CTX (100 mg/d) /CsA (200 mg/d)	+	+	+	+	OU	–	20/33	20/16	43
4	F	50	20	Insufficient dosing	20/2000	20/400	CTX (100 mg/d)	+	+	–	+	OU	–	20/133	20/100	61
5	M	42	60	Over-rapid tapering	20/660	20/400	CsA (200 mg/d)	+	+	+	+	OU	OD	20/200	20/200	25
6	M	31	28	Over-rapid tapering	20/2000	20/2000	CsA (200 mg/d)	+	–	+	+	OU	OU	20/250	20/50	42
7	F	55	37	Over-rapid tapering	20/100	20/660	CsA (150 mg/d)	+	+	+	–	OU	OS	20/80	20/100	57
8	F	58	20	Insufficient dosing	20/660	20/660	CsA (150 mg/d)	+	+	+	+	–	–	20/25	20/25	24
9	F	36	35	Over-rapid tapering	20/2000	20/2000	CsA (150 mg/d)	+	–	–	–	–	–	20/20	20/20	24
10	M	25	50	Over-rapid tapering	20/2000	20/2000	CsA (200 mg/d)	+	–	–	–	–	–	20/16	20/20	13

Abbreviations: Pt patient, G gender, F female, M male, DFV duration at first visit, CS corticosteroid treatment, IMT immunomodulatory treatment, CsA cyclosporin A, CTX cyclophosphamide, AZA azathioprine, IBCV initial best corrected visual acuity, RAU recurrent anterior uveitis, ME macular edema, MA macular atrophy, IOL intraocular lens, MI macular involvement, SRFRS SRF removal surgery, FBCV final best corrected visual acuity
“+” denotes positive for the indicated finding/surgery in at least one eye while “-” denotes negative
^a: inappropriate initial corticosteroid treatment for longer than 2 weeks before being presented to our center

ISSN: 1471-2415